Expanded access to highly validated monospecific antibodies

Amsbio has significantly expanded its portfolio of recombinant and monoclonal antibodies with the addition of more than 10,000 newly validated monospecific products, available in 15,000 formulations to support research across cancer biology, immunology, neuroscience and signal transduction.

Each antibody in the expanded range has undergone extensive validation to confirm selective target recognition across key applications including immunohistochemistry, western blotting, flow cytometry and immunofluorescence. Designed to deliver high sensitivity with minimal background interference, the antibodies help reduce false positives and minimise non-specific binding during experimental workflows.

Recombinant antibodies, produced using advanced genetic engineering techniques, are increasingly valued for their precision, consistency and reproducibility. Their scalability, customisation potential and reduced immunogenicity make them important tools in both research and therapeutic development. Monoclonal antibodies, meanwhile, offer highly specific recognition of single epitopes, making them essential for targeted disease research, diagnostics and treatment development in areas such as cancer and autoimmune disorders.

Produced through tightly controlled manufacturing processes, the monospecific antibodies offer exceptional batch-to-batch consistency, an important factor for long-term studies and reproducible experimental results. Each product has been developed and tested across hundreds of tumour types and normal tissues to ensure accurate epitope mapping and strong binding affinity.

More information online